Additionally, apatinib has been identified as a ferroptosis promoter in CRC cells by targeting the ELOVL6/ACSL4 pathway, suggesting its potential as a valuable addition to CRC treatment strategies [121]. Here, ACSL4 is linked to colorectal carcinoma.